local_hospital

Rode Kruis Ziekenhuis B.V.

Address
lock Available on a paid plan

Cardiovascular Diseases

At Rode Kruis Ziekenhuis B.V., a major share of the research focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, peripheral arterial disease, and prevention of stroke and myocardial infarction. These studies are designed to test new treatments and compare them with current care to better reduce serious heart and blood vessel complications.

  • Prevention of major cardiovascular events in high-risk patients
  • Treatment strategies for atrial fibrillation and stroke prevention
  • Therapies for heart failure, obesity, and vascular disease
  • Improving lipid-lowering approaches for cardiovascular risk reduction

Overall, the cardiology department in Beverwijk is contributing to research that aims to make cardiovascular care safer, more effective, and better tailored to patients at elevated risk.

Oncology and Hematologic Diseases

This site is also involved in studies across neoplasms and hemic and lymphatic diseases, including breast cancer, triple negative breast cancer, metastatic colorectal cancer, multiple myeloma, and prostate cancer. The research is centered on evaluating treatment effectiveness, refining treatment sequences, and exploring ways to reduce toxicity while preserving cancer control.

  • New approaches for breast cancer and triple negative breast cancer
  • Optimizing treatment plans in metastatic colorectal cancer and multiple myeloma
  • Testing whether treatment breaks or modified strategies can maintain control in prostate cancer
  • Assessing cancer-associated clotting prevention in patients with venous thromboembolism

These trials reflect a broad oncology portfolio that seeks to improve outcomes while making therapy more manageable for patients.

Burns, Skin Repair, and Surgical Wound Care

Another important research area at Rode Kruis Ziekenhuis B.V. involves skin and connective tissue diseases and therapeutic techniques and equipment, with studies in burn injury, full-thickness skin defects, and complex wound healing. These trials are evaluating new skin graft products and wound treatments to improve closure, reduce scarring, and support recovery after severe injuries.

  • New skin graft options for adults and children with burns or large skin defects
  • Improving wound closure and scar quality after grafting
  • Reducing blood loss during burn surgery
  • Testing better surgical support for complex burn care

The focus is on practical innovations that could make reconstructive and burn treatment more effective for both children and adults.

Digestive, Metabolic, and Endocrine Conditions

The site conducts clinical research in digestive system diseases, nutritional and metabolic diseases, and hormonal diseases, including appendicitis, obesity, type 2 diabetes, and secondary hyperparathyroidism. These studies aim to improve postoperative recovery, support weight management, and assess treatments that may better control metabolic complications.

  • Preventing complications after surgery for complicated appendicitis
  • Supporting weight loss after bariatric surgery in patients who respond poorly
  • Testing hormone-related treatment after gastric bypass surgery
  • Evaluating new options for diabetes, obesity, and related cardiovascular risk

This research brings together surgical, metabolic, and endocrine care with the goal of improving long-term patient outcomes.

Women’s and Male Urogenital Health

Research in female urogenital diseases and pregnancy complications and male urogenital diseases includes studies of placenta previa, preterm birth, and low-volume metastatic castration-sensitive prostate cancer. The main purpose is to evaluate strategies that may improve pregnancy outcomes or help patients maintain cancer control while reducing unnecessary treatment burden.

  • Preventing preterm birth in women with placenta previa
  • Exploring treatment de-escalation in prostate cancer
  • Balancing effectiveness and quality of life in reproductive and urologic care
  • Supporting safer, more individualized treatment decisions

These studies show a focus on carefully targeted care in both maternity-related and male urologic conditions.

Site Overview

assignment
27
connected trials
corporate_fare
21
sponsors
science
53
IMPs

Activity Indicator

Last 6 months

4
Trials started
+300% vs previous period.
1
Trials started 6–12 months ago
27
Total trials linked
Highly Active
trending_upGrowing+300%
2
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 11 therapeutic areas and 15 of 53 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 49 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
15
Sponsors (total)
21
Active sponsors
14

Sponsor Network

Top 14 by active trials.

lock +13 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
27
Outperforms 78% of sites
public
Therapeutic diversity
11areas
Outperforms 80% of sites
groups
Sponsor diversity
21sponsors
Outperforms 80% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Rode Kruis Ziekenhuis B.V.

lock Showing 1 of 27 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF HospitalizationNovo Nordisk A/SPhase IIIRecruitingApr 2026

IMP list

lock Showing 1 of 53 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts4Unknown2019-01-142024-12-06

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.